Luise Sophie Ammer1,2, Sandra Pohl2,3, Sandra Rafaela Breyer2,4,5, Charlotte Aries1,2, Jonas Denecke1, Anna Perez1,2, Martin Petzoldt6, Johanna Schrum7, Ingo Müller7, Nicole Maria Muschol1,2. 1. Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2. International Center for Lysosomal Disorders (ICLD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4. Department of Pediatric Orthopedics, Children's Hospital Altona, Hamburg, Germany. 5. Department of Orthopedics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 6. Department of Anesthesiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 7. Division of Pediatric Stem Cell Transplantation and Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
BACKGROUND: Mucolipidosis type II (MLII) is an ultra-rare lysosomal storage disorder caused by defective lysosomal enzyme trafficking. Clinical hallmarks are craniofacial dysmorphia, cardiorespiratory dysfunction, hepatosplenomegaly, skeletal deformities and neurocognitive retardation. Death usually occurs in the first decade of life and no cure exists. Hematopoietic stem cell transplantation (HSCT) has been performed in few MLII patients, but comprehensive follow-up data are extremely scarce. METHODS: MLII diagnosis was confirmed in a female three-month-old patient with the mutations c.2213C > A and c.2220_2221dup in the GNPTAB gene. At nine months of age, the patient received HSCT from a 9/10 human leukocyte antigen (HLA)-matched unrelated donor. RESULTS: HSCT resulted in a sustained reduction of lysosomal storage und bone metabolism markers. At six years of age, the patient showed normal cardiac function, partial respiratory insufficiency and moderate hepatomegaly, whereas skeletal manifestations had progressed. However, the patient could walk and maintained an overall good quality of life. Neurocognitive testing revealed a developmental quotient of 36%. The patient died at 6.6 years of age following a human metapneumovirus (hMPV) pneumonia. CONCLUSIONS: The exact benefit remains unclear as current literature vastly lacks comparable data on MLII natural history patients. In order to evaluate experimental therapies, in-depth prospective studies and registries of untreated MLII patients are indispensable.
BACKGROUND: Mucolipidosis type II (MLII) is an ultra-rare lysosomal storage disorder caused by defective lysosomal enzyme trafficking. Clinical hallmarks are craniofacial dysmorphia, cardiorespiratory dysfunction, hepatosplenomegaly, skeletal deformities and neurocognitive retardation. Death usually occurs in the first decade of life and no cure exists. Hematopoietic stem cell transplantation (HSCT) has been performed in few MLII patients, but comprehensive follow-up data are extremely scarce. METHODS: MLII diagnosis was confirmed in a female three-month-old patient with the mutations c.2213C > A and c.2220_2221dup in the GNPTAB gene. At nine months of age, the patient received HSCT from a 9/10 human leukocyte antigen (HLA)-matched unrelated donor. RESULTS: HSCT resulted in a sustained reduction of lysosomal storage und bone metabolism markers. At six years of age, the patient showed normal cardiac function, partial respiratory insufficiency and moderate hepatomegaly, whereas skeletal manifestations had progressed. However, the patient could walk and maintained an overall good quality of life. Neurocognitive testing revealed a developmental quotient of 36%. The patient died at 6.6 years of age following a human metapneumovirus (hMPV) pneumonia. CONCLUSIONS: The exact benefit remains unclear as current literature vastly lacks comparable data on MLII natural history patients. In order to evaluate experimental therapies, in-depth prospective studies and registries of untreated MLII patients are indispensable.
Authors: Renata Voltolini Velho; Frederike L Harms; Tatyana Danyukova; Nataniel F Ludwig; Michael J Friez; Sara S Cathey; Mirella Filocamo; Barbara Tappino; Nilay Güneş; Beyhan Tüysüz; Karen L Tylee; Kathryn L Brammeier; Lesley Heptinstall; Esmee Oussoren; Ans T van der Ploeg; Christine Petersen; Sandra Alves; Gloria Durán Saavedra; Ida V Schwartz; Nicole Muschol; Kerstin Kutsche; Sandra Pohl Journal: Hum Mutat Date: 2019-04-13 Impact factor: 4.878
Authors: Minke H de Ru; Jaap J Boelens; Anibh M Das; Simon A Jones; Johanna H van der Lee; Nizar Mahlaoui; Eugen Mengel; Martin Offringa; Anne O'Meara; Rossella Parini; Attilio Rovelli; Karl-Walter Sykora; Vassili Valayannopoulos; Ashok Vellodi; Robert F Wynn; Frits A Wijburg Journal: Orphanet J Rare Dis Date: 2011-08-10 Impact factor: 4.123
Authors: Giorgia Di Lorenzo; Lena M Westermann; Timur A Yorgan; Julian Stürznickel; Nataniel F Ludwig; Luise S Ammer; Anke Baranowsky; Shiva Ahmadi; Elham Pourbarkhordariesfandabadi; Sandra R Breyer; Tim N Board; Anne Foster; Jean Mercer; Karen Tylee; Renata Voltolini Velho; Michaela Schweizer; Thomas Renné; Thomas Braulke; Dévora N Randon; Fernanda Sperb-Ludwig; Louise Lapagesse de Camargo Pinto; Carolina Araujo Moreno; Denise P Cavalcanti; Michael Amling; Kerstin Kutsche; Dominic Winter; Nicole M Muschol; Ida V D Schwartz; Tim Rolvien; Tatyana Danyukova; Thorsten Schinke; Sandra Pohl Journal: Genet Med Date: 2021-08-02 Impact factor: 8.822